ME02575B - Farmaceutska kompozicija - Google Patents
Farmaceutska kompozicijaInfo
- Publication number
- ME02575B ME02575B MEP-2017-3A MEP317A ME02575B ME 02575 B ME02575 B ME 02575B ME P317 A MEP317 A ME P317A ME 02575 B ME02575 B ME 02575B
- Authority
- ME
- Montenegro
- Prior art keywords
- methyl
- hydrogen
- cancer
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 46
- 239000001257 hydrogen Substances 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 28
- 150000002431 hydrogen Chemical group 0.000 claims 21
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 20
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 201000004435 urinary system cancer Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- -1 methoxy, difluoromethoxy Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 | |
| EP11760631.9A EP2619182B1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
| PCT/US2011/051163 WO2012039972A1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02575B true ME02575B (me) | 2017-06-20 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-3A ME02575B (me) | 2010-09-21 | 2011-09-12 | Farmaceutska kompozicija |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (OSRAM) |
| EP (2) | EP2619182B1 (OSRAM) |
| JP (1) | JP5956448B2 (OSRAM) |
| KR (1) | KR101911105B1 (OSRAM) |
| CN (1) | CN103097358B (OSRAM) |
| AU (1) | AU2011305872B2 (OSRAM) |
| BR (1) | BR112013002484B1 (OSRAM) |
| CA (1) | CA2806121C (OSRAM) |
| CL (1) | CL2013000675A1 (OSRAM) |
| CY (1) | CY1118680T1 (OSRAM) |
| DK (1) | DK2619182T3 (OSRAM) |
| ES (1) | ES2610185T3 (OSRAM) |
| HR (1) | HRP20170042T1 (OSRAM) |
| HU (1) | HUE031408T2 (OSRAM) |
| IL (1) | IL224288A (OSRAM) |
| LT (1) | LT2619182T (OSRAM) |
| ME (1) | ME02575B (OSRAM) |
| MX (1) | MX2013003162A (OSRAM) |
| MY (1) | MY162146A (OSRAM) |
| NZ (1) | NZ606629A (OSRAM) |
| PE (1) | PE20131343A1 (OSRAM) |
| PH (1) | PH12013500467A1 (OSRAM) |
| PL (1) | PL2619182T3 (OSRAM) |
| PT (1) | PT2619182T (OSRAM) |
| RS (1) | RS55566B1 (OSRAM) |
| RU (1) | RU2606510C2 (OSRAM) |
| SG (1) | SG188188A1 (OSRAM) |
| SI (1) | SI2619182T1 (OSRAM) |
| SM (2) | SMT201700008T1 (OSRAM) |
| UA (1) | UA113499C2 (OSRAM) |
| WO (1) | WO2012039972A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| RS57406B1 (sr) | 2013-06-12 | 2018-09-28 | Kaken Pharmaceutical Co Ltd | Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| SG11201609770TA (en) * | 2014-05-23 | 2016-12-29 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of cancer |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| EP3325490B1 (en) | 2015-07-23 | 2019-12-18 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| AU2016338679B2 (en) * | 2015-10-16 | 2021-05-06 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| HRP20211380T1 (hr) | 2017-05-18 | 2021-11-26 | Idorsia Pharmaceuticals Ltd | Derivati pirimidina kao modulatori receptora pge2 |
| SI3625224T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | N-substituirani indolni derivati |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| US20200352906A1 (en) * | 2018-02-05 | 2020-11-12 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases |
| AU2021229414B2 (en) * | 2020-03-04 | 2023-07-06 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Synthesis of novel EP4 antagonist and use in cancers and inflammations |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
| TWI877433B (zh) | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| WO2022161418A1 (zh) * | 2021-01-28 | 2022-08-04 | 深圳晶泰科技有限公司 | 吡唑酰胺衍生物及其制备方法和应用 |
| CA3230557A1 (en) * | 2021-09-03 | 2023-03-09 | Xuejun Zhang | Ep4 antagonist compound as well as salt, polymorph, and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| CN118414328A (zh) | 2021-12-23 | 2024-07-30 | 卫材R&D管理有限公司 | Ep4拮抗剂的结晶盐形式 |
| US20250381143A1 (en) * | 2021-12-30 | 2025-12-18 | Adlai Nortye Biopharma Co., Ltd. | A solid pharmaceutical composition |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| BRPI0411825B8 (pt) * | 2003-06-26 | 2021-05-25 | Novartis Ag | inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica |
| ES2441206T3 (es) | 2003-09-03 | 2014-02-03 | Raqualia Pharma Inc. | Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2 |
| WO2005070889A1 (en) | 2004-01-23 | 2005-08-04 | E.I. Dupont De Nemours And Company | Herbicidal amides |
| ES2327760T3 (es) * | 2004-05-04 | 2009-11-03 | Raqualia Pharma Inc | Compuestos de aril-heteroaril-amida ortosustituidos. |
| WO2005105732A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| WO2006134318A1 (en) * | 2005-06-11 | 2006-12-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| BRPI0618885A8 (pt) | 2005-11-21 | 2018-06-26 | Shionogi & Co | compostos heterocíclicos tendo atividade inibitória de 11beta-hidroxiesteroide deidrogenase tipo i |
| WO2007091570A1 (ja) * | 2006-02-06 | 2007-08-16 | Taisho Pharmaceutical Co., Ltd. | スフィンゴシン－１－リン酸結合阻害物質 |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| WO2008017164A1 (en) | 2006-08-11 | 2008-02-14 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| CA2672631A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
| JP5301469B2 (ja) | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| CA2690460A1 (en) | 2007-06-15 | 2008-12-18 | Markus Nett | Method for producing difluoromethyl-substituted pyrazole compounds |
| EP2460787A1 (en) * | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Amide compounds and their use as PGE2 antagonists. |
| SG187396A1 (en) | 2007-07-19 | 2013-02-28 | Lundbeck & Co As H | 5-membered heterocyclic amides and related compounds |
| CL2008002241A1 (es) | 2007-07-31 | 2009-12-28 | Bayer Cropscience Sa | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| EP2297112B1 (en) * | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| KR101612971B1 (ko) | 2008-05-14 | 2016-04-15 | 아스테라스 세이야쿠 가부시키가이샤 | 아미드 화합물 |
| MX2011001066A (es) | 2008-08-01 | 2011-03-24 | Bayer Cropscience Ag | Derivados de n-cicloalquil-n-bifenilmetil-carboxamida fungicidas. |
| CA2733247C (en) * | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| AU2009295308A1 (en) | 2008-09-25 | 2010-04-01 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists |
-
2011
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 SM SM20170008T patent/SMT201700008T1/it unknown
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en not_active Ceased
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
- 2011-09-12 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
- 2011-09-12 PH PH1/2013/500467A patent/PH12013500467A1/en unknown
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active Active
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02575B (me) | Farmaceutska kompozicija | |
| JP2013538825A5 (OSRAM) | ||
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| JP2017536686A5 (OSRAM) | ||
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| SI1881967T1 (sl) | Substituirane benzo(d)izoksazol-3-il-aminske spojine kot analgetiki | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| ME02800B (me) | Nova triciklična jedinjenja | |
| PH12012501418A1 (en) | New foamed concrete | |
| BRPI0923728A2 (pt) | "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase". | |
| ME02171B (me) | Spoj za inhibiciju notch signalnog puta | |
| AR108265A1 (es) | Derivados de feniltriazol sustituidos con amida y usos de estos | |
| NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| MY190196A (en) | Diazacarbazole derivatives as tau-pet-ligands | |
| MX383551B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida | |
| MX352546B (es) | Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo. | |
| HRP20191837T1 (hr) | Postupak za pripremu 5-fluoro-1h-pirazola počevši od heksafluoropropena | |
| MY159842A (en) | Plant disease control composition and its use | |
| EA201290055A1 (ru) | Новый способ грануляции и полученный с его помощью гранулят | |
| GEP20146019B (en) | Novel method of synthesizing ivabradine and pharmaceutically acceptable acid-additive salts thereof | |
| TN2018000126A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
| AR099943A1 (es) | Derivados quirales de ácido ciclopentancarboxílico 2,5-disustituidos y su uso |